Skip to content

A new three-dimensional printed bolus technique for optimization of superficail lesions irradiation

Clinical application of a new three-dimensional printed bolus technique for optimization of superficail lesions irradiation

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015032
Enrollment
Unknown
Registered
2018-03-01
Start date
2017-02-21
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

superficail lesions

Interventions

3D bolus:using 3D bolus

Sponsors

Delpartment of Radiation Oncology, Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with superficial tumor, who need precision radiotherapy for multiple times; 2. Intensity modulated radiotherapy (IMRT) is expected to be applied; 3. Patients with clear consciousness who can cooperate with setup and treatment; 4. Eastern Cooperative Oncology Group Performance Status Scale (ECOG-PS) =2; 5. Aged 18 years or elder; non-pregnant women; 6. Agree to participate in necessary examination and follow-up for research purpose and to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients for whom that the flat bolus is effective; 2. Patients who need emergency radiotherapy or whose tumor grows too fast to make the 3D printing bolus because of their big changes in body surface; 3. Patients with serious local pain, for whom 3D printing bolus cannot be tolerate; 4. Eastern Cooperative Oncology Group Performance Status Scale (ECOG-PS) >2; 5. Patients with sever emental disease or psychological obstacle, or dysfunction of the central nervous system, or cardio-cerebrovascular complications, or epilepsy etc. Patients with poor compliance or cannot provide written informed consent; 6. Cannot cooperate with treatment for other reasons; 7. Pregnant women or breast-feeding women; fertile women with urine or blood pregnant tests positive two weeks before inclusion or fertile women without reliable contraceptive measures; 8. Patients with severe and uncontrolled infectious diseases; 9. Patients with other uncontrolled diseases which may affect the study.

Design outcomes

Primary

MeasureTime frame
set-up error;dose volume parameters;

Contacts

Public ContactXian-shu Gao

Peking University First Hospital

gao7777@139.com+86 13911208977

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026